Taysha Gene Therapies, Inc. TSHA Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $319.77M+130% | $139.04M-3.4% | $143.94M+63.8% | $87.88M-41.1% | ||
| $324.65M+128% | $142.13M-5.2% | $149.87M+55.4% | $96.42M-39.6% | ||
| $6.74M-10.0% | $7.49M-30.9% | $10.83M-27.6% | $14.96M-70.4% | ||
| $343.32M+114% | $160.36M-7.2% | $172.73M+36.8% | $126.28M-41.0% | ||
| $23.75M-14.0% | $27.62M-17.9% | $33.65M-53.4% | $72.16M+33.0% | ||
| —— | $9.77M-46.0% | $18.11M-46.0% | $33.56M— | ||
| $26.55M+1.2% | $26.23M-28.6% | $36.76M-41.5% | $62.79M+21.3% | ||
| $50.11M+14.0% | $43.94M+8.5% | $40.51M+6.7% | $37.97M+2.1% | ||
| $96.38M+8.5% | $88.84M-9.2% | $97.79M-22.0% | $125.33M+5.7% | ||
| $3K+50.0% | $2K0.0% | $2K+100% | $1K— | ||
| -$711.3M-18.1% | -$602.31M-17.4% | -$513.01M-27.8% | -$401.44M-70.4% | ||
| $246.94M+245% | $71.53M-4.6% | $74.94M+7,796% | $949K-99.0% | ||
| $343.32M+114% | $160.36M-7.2% | $172.73M+36.8% | $126.28M-41.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Taysha Gene Therapies, Inc. cover its short-term obligations?
- Its current ratio is 14.04 — current assets exceed current liabilities.
- Where does Taysha Gene Therapies, Inc.'s balance sheet data come from?
- Every line is extracted from Taysha Gene Therapies, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.